生物制剂在儿童狼疮性肾炎中的治疗进展  

Progress in the treatment of biological agents in children's lupus nephritis

作　　者：李梦阳 包瑛[2] LI Mengyang;BAO Ying(Xi'an Medical College,Xi'an,Shaanxi,710000,China;Department of Nephrology,Xi'an Children's Hospital,Xi'an,Shaanxi,710000,China)

机构地区：[1]西安医学院,陕西西安710000 [2]西安市儿童医院肾脏内科,陕西西安710000

出　　处：《当代医学》2024年第1期179-183,共5页Contemporary Medicine

摘　　要：儿童狼疮性肾炎是儿童系统性红斑狼疮最常见、最严重的并发症,在儿童终末期肾脏疾病中占有重要地位。目前,临床治疗LN主要采用糖皮质激素和免疫抑制剂,患者遭受其严重不良反应,如库欣综合征、内分泌代谢异常(骨质疏松、高血糖)、生长发育抑制、高眼压、免疫功能低下易感染、骨髓抑制等。近年来,随着对生物制剂作用机制研究更为深入,生物制剂治疗LN受到大家的青睐,本文旨在对近年来国内外生物制剂在儿童LN中的治疗进展作一综述。Childhood lupus nephritisis(LN)the most common and severe complication of childhood systemic lupus erythematosus,and plays an important role in end-stage renal disease in children.LN is currently treated with glucocorticoid and immunosuppressants,and patients suffer from se-rious side effects,such as Cushing's syndrome,endocrine metabolic abnormalities(osteoporosis,hyperglycemia),growth inhibition,high intraocular pressure,immune dysfunction susceptible to infection,bone marrow suppression.In recent years,the mechanism of action of biological agents has been studied more deeply,and biological agents have been widely used in the treatment of LN,this article reviews the progress of biological agents in the treatment of LN in children at home and abroad in recent years.

关 键 词：儿童 系统性红斑狼疮 狼疮性肾炎 生物制剂 

分 类 号：R593.242[医药卫生—内科学]